Last checked at 1 Mar 2018 07:00
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Align Research Initiation of Coverage
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that Align Research ("Align")has today initiated research coverage on the Company. The Company is pleased to note the comments of Align in their research note ("Note") including its "conviction buy" stance and target price of 18.15 pence. However, the Board wishes to emphasize that the views expressed in the Note are those of Align alone.
The Note should be read in full. To download it visit:
http://www.alignresearch.co.uk/cpt-company/hemogenyx-pharmaceuticals/ or www.hemogenyx.com/research/
As always shareholders should speak to their own financial adviser before entering into any dealings in the Company's shares. In particular, whilst the Company confirms the views attributed to it in the Note on recent trading, there is no certainty that the possible future collaborations and the Board's great confidence can be realized in full or within the Company's current development timetable. The views expressed by Align on the Company's valuation and prospects are a matter of opinion and the Company is in no position to comment on whether they are accurate.
The Company also wishes to draw attention to the key risks identified by Align and its disclaimer and risk warning and the qualifications that it makes in its conclusion to the Note. Shareholders should also note that the Company is a research client of Align and that Align holds shares in the Company
Enquiries:
Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
Dr Robin Campbell, Chairman |
| |
|
| |
Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
Christian Dennis |
| |
|
| |
Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 | |
Damon Heath, Erik Woolgar |
| |
|
| |
Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
Lucy Williams/Duncan Vasey |
| |
|
| |
Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
|
| |
US Media enquiries |
| |
Lowell Goodman | Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net | |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.
For more information, visit www.hemogenyx.com.